SAN DIEGO, May 9, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012. First quarter 2013 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 38% as compared to the fourth quarter of 2012. "The volume of 35,000 MaterniT21™ PLUS tests accessioned in the first quarter shows that Sequenom CMM continued to take advantage of its first mover position in the non-invasive prenatal diagnostic (NIPT) market by increasing its penetration of the NIPT market and maintaining its dominant market share. The recent announcement that Sequenom CMM had accessioned over 100,000 MaterniT21 PLUS test samples since the test was launched in October of 2011 is further evidence of the remarkable success of...
Read More >>
SAN DIEGO, May 8, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Bank of America Merrill Lynch Health Care Conference at the Encore at the Wynn Hotel in Las Vegas, NV on May 14-16, 2013. Paul V. Maier, Chief Financial Officer, will present on Thursday, May 16, 2013 beginning at 12:00 p.m. PDT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target...
Read More >>
SAN DIEGO, April 25, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2013 after closing of the NASDAQ Global Market on Thursday, May 9, 2013.A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website. To access the live teleconference call, dial 800-860-2442 in the U.S. and 412-858-4600 for international callers. Please specify to the operator that you would like to join the "Sequenom First Quarter 2013 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available until Friday, May 17, 2013. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and...
Read More >>
SAN DIEGO, April 16, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that earlier this month, its wholly owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), surpassed 100,000 MaterniT21™ PLUS test samples processed since the launch of its laboratory developed test (LDT) in October of 2011. The MaterniT21 PLUS test was the first commercial non-invasive prenatal test (NIPT) of its kind for the detection of a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome."There has been a significant clinical benefit of incorporating NIPT technology, such as the MaterniT21 PLUS test, into my practice, and I expect to see this technology utilized as a best practice tool among women at high risk of fetal aneuploidy," said Arnold Cohen, MD, Chairman, Department of Obstetrics and Gynecology, Albert Einstein Medical Center in Philadelphia. "The...
Read More >>
SAN DIEGO, March 21, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Sequenom Center for Molecular Medicine (SCMM) has launched an advanced new cystic fibrosis carrier screen test branded under the name Heredi-T™. The laboratory-developed test (LDT) is now available as a testing service to ordering physicians.The Heredi-T Cystic Fibrosis (CF) test analyzes 136 mutations and five variants proven to be clinically relevant in causing CF, integrating disease causing mutations selected from the Johns Hopkins CFTR2 database (http://www.cftr2.org). The LDT analyzes nearly six times the number of mutations currently available in other screening methods and can be performed preconception or at any time during pregnancy with a DNA sample obtained from a buccal swab. "The Heredi-T test provides significant new clinical value, offering highly reliable information about a patient's risk of being...
Read More >>
SAN DIEGO, March 15, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the 25th Annual Roth Conference at the Ritz-Carlton Hotel in Laguna Niguel, CA on March 17-20, 2013. William Welch, M.B.A, President and Chief Operating Officer, will present on Monday, March 18, 2013, beginning at 12:30 p.m. PT, to provide an overview of and update on the Company. The presentation is expected to last approximately 25 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target...
Read More >>
SAN DIEGO, March 7, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $33.7 million and $89.7 million for the fourth quarter and full year of 2012, respectively. Net loss was $32.8 million, or $0.29 per share, and $117.1 million, or $1.03 per share, for the fourth quarter and full year, respectively. "It has been a little more than one year since the Sequenom Center for Molecular Medicine (SCMM) launched MaterniT21 PLUS™, the first non-invasive prenatal test (NIPT) in the United States that measures circulating cell-free nucleic acids in maternal blood for the detection of fetal aneuploidies. During 2012, SCMM established itself as the leader in the NIPT field with the good acceptance of MaterniT21 PLUS by the medical community," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "SCMM and its licensees have also seen rapid acceptance of non-invasive prenatal...
Read More >>
SAN DIEGO, March 5, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Barclays Global Healthcare Conference at the Loews Miami Hotel in Miami, FL on March 12-14, 2013. Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present on Wednesday, March 13, 2013, beginning at 4:45 p.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 25 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that...
Read More >>
SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the fourth quarter and full year of 2012 after closing of the NASDAQ Global Market on Thursday, March 7, 2013.A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website. To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Fourth Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Friday, March 15, 2013. Interested parties can access the...
Read More >>
SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced today that the MaterniT21™ PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain fetal sex chromosomal aneuploidies, in addition to its identification of autosomal aneuploidies for chromosome 21 (associated with Down syndrome), chromosome 18 (associated with Edwards syndrome), and chromosome 13 (associated with Patau syndrome). Reporting of these sex aneuploidies will begin for samples received as of Monday, February 4, 2013.The test will report on the presence of four rare aneuploidies involving an abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY (Klinefelter Syndrome) and 47,XYY...
Read More >>
SAN DIEGO, Jan. 6, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced preliminary highlights of the Company's 2012 performance and accomplishments.
Initial 2012 Performance Results (unaudited)
Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012
Diagnostic services revenues of approximately $46 million, compared to $8.3 million in 2011. Diagnostic services revenues continue to be recorded primarily as cash is received
Sales in the Genetic Analysis business of approximately $43 million
More than 92,000 total prenatal and retinal diagnostic tests accessioned during the year
Strong increases in the adoption rate and sales of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS lab-developed test (LDT):
More than 60,000 MaterniT21 PLUS tests accessioned in 2012 An...
Read More >>
SAN DIEGO, Jan. 2, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming 31st Annual JP Morgan Healthcare Conference, to be hosted at the Westin St. Francis Hotel in San Francisco, CA. On Wednesday, January 9th, Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present starting at 11:30 am PT (2:30 pm ET) to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions...
Read More >>
SAN DIEGO, Dec. 14, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter. Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent. About SequenomSequenom, Inc. (NASDAQ...
Read More >>
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) announced today the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately. Additionally, Ronald Lindsay has been named as the Company's Executive Vice President, Strategic Planning. Harry F. Hixson, Jr. will continue to serve as Chairman and Chief Executive Officer.Mr. Welch joined Sequenom in January 2011 as Senior Vice President, Diagnostics. He has overseen the Company's commercial operations in connection with the October 2011 launch of its MaterniT21 PLUS laboratory-developed test. "Bill's extensive industry experience and knowledge have been a significant asset to Sequenom over the last two years as we launched the MaterniT21 PLUS test," said Harry Hixson, Jr., Chairman and Chief Executive Officer. "This promotion reflects his...
Read More >>
SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent No. 8,340,916 on December 25, 2012 with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego...
Read More >>
SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming Oppenheimer 23rd Annual Healthcare Conference, to be hosted at the Waldorf Astoria in New York, NY. On Thursday, December 13, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development and Paul V. Maier, Chief Financial Officer, will present starting at 10:00 am ET to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops...
Read More >>
SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics and the Society for Maternal-Fetal Medicine (SMFM) Publications Committee issued a joint Committee Opinion on November 20, 2012, recommending that cell-free fetal DNA testing be offered to patients at increased risk of aneuploidy. It can also be used as a follow-up test for women with a positive first-trimester or second-trimester screening test result. Previously, the ACOG recommended that women, regardless of maternal age, be offered prenatal assessment for aneuploidy by screening or invasive prenatal diagnosis. The ACOG Committee on Genetics and the SMFM Publications Committee now recommend that women at increased risk of aneuploidy be offered cell-free fetal DNA as an option that can be used as a primary...
Read More >>
SAN DIEGO, Nov. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.This Sequenom CMM laboratory-developed genetic test (LDT) combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization (CNV) disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration (AMD), in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately...
Read More >>
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $22.9 million for the third quarter of 2012, an increase of 25% from revenue of $18.3 million in the second quarter of 2012 and a 68% increase compared to revenue of $13.6 million for the third quarter of 2011. Revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostic testing services operating segment grew to $12.5 million in the third quarter of 2012, while revenues from the genetic analysis operating segment were $10.4 million in the third quarter of 2012. Also during the third quarter of 2012, Sequenom CMM established a number of new agreements with networks and insurance providers, increasing the number of lives covered with in-network access to the MaterniT21 PLUS laboratory developed test (LDT) from 26 million to 46 million. "The results from this quarter illustrate the impact of...
Read More >>
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference in New York and the Jefferies 2012 Global Healthcare Conference in London. On Tuesday, November 13, Harry F. Hixson Jr., Ph.D., Sequenom's Chief Executive Officer, will present at the Lazard Capital Markets 9th Annual Healthcare Conference, starting at 9:30 am ET to provide an overview of and update on the Company. Then, on Thursday, November 15, Dr. Hixson will present at the Jefferies 2012 Global Healthcare Conference, starting at 2:20 pm GMT. Both presentations are expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. Audio replays will be available for 30 days following the initial presentation webcasts. About...
Read More >>
SAN DIEGO, Oct. 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the California Technology Assessment Forum completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS™ laboratory-developed test (LDT). CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes. Blue Shield of California Foundation (BSCF) spearheads the California Technology Assessment Forum (CTAF), which was established to assess new and emerging medical technology. CTAF is one of the preeminent independent medical technology assessment organizations in the country. A multidisciplinary group of medical providers...
Read More >>
SAN DIEGO, Oct. 15, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the third quarter of 2012 after closing of the NASDAQ Global Market on Thursday, November 8, 2012.A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website. To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Third Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday, November 15, 2012. Interested parties can access the...
Read More >>
SAN DIEGO, Oct. 11, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the appointment of Bill Bowen as Senior Vice President and General Counsel. Mr. Bowen will report to Dr. Harry F. Hixson, Chairman and CEO and will be responsible for all company legal and patent activities. "With Mr. Bowen's extensive expertise in biotechnology and medical device corporate counsel, he brings the critical skills to help guide the company with strategic legal and patent strategies as we continue to evolve our offerings in the genetic analysis marketplace," said Harry F. Hixson, Jr., Ph.D., chairman and chief executive officer. "By having Bill join us, Sequenom gains a leader who has experience in the diagnostics environment with a company that has been on a growth track similar to the one that we are on currently."Mr. Bowen was previously employed with Gen-Probe Incorporated, a San Diego-based molecular...
Read More >>
SAN DIEGO, Sept. 17, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of its offering of $130.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering, including $20.0 million aggregate principal amount of notes sold pursuant to the full exercise of an over-allotment option previously granted to the initial purchasers. Sequenom intends to use the net proceeds from this offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses.About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve...
Read More >>
SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of its offering of $110.0 million aggregate principal amount of Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering. The sale of the Convertible Notes is expected to close on September 17, 2012, subject to customary closing conditions. Sequenom also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0 million aggregate principal amount of the Convertible Notes solely to cover over-allotments, if any. Sequenom intends to use the net proceeds from this offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses.The Convertible Notes will be the senior, unsecured obligations of Sequenom. They...
Read More >>
News Release Archive >>
|